Astellas Pharma
OverviewSuggest Edit
Astellas Pharma is a pharmaceutical company focused on the development of drugs and medical solutions. Its focus areas include urology, immunology, cardiology, infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system. Astellas Pharma's main products include XTANDI, an androgen receptor signaling inhibitor indicated for the treatment of forms of advanced prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation-positive; PADCEV, a treatment for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); Evrenzo, an oral treatment for anemia associated with chronic kidney disease (CKD), and Prograf and Advagraf/Graceptor/ASTAGRAF, immunosuppressants used to suppress organ rejection following a transplant.
| Type | Public | |
| Founded | 1923 | |
| HQ | Tokyo, JP | Map |
| Website | astellas.com | |
| Employee Ratings | More | |
| Overall Culture | F | More |
Recent NewsAll News
- Astellas and MBC BioLabs Announce Winners of Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery and Innovation
- KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus
- Astellas and Viatris Announce Termination of Co-promotion, Succession of Manufacturing and Marketing Approval, and Transfer of Distribution for Celecox® Tablets
- Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
Key People/Management at Astellas Pharma
Yoshihiko Hatanaka
Shontelle Dodson
Kenji Yasukawa
Lynn Fenicchia
Mamoru Sekiyama
Moyra Knight
Astellas Pharma Office Locations
Astellas Pharma Financials and Metrics
Astellas Pharma Revenue
| JPY | |
|---|---|
Revenue (H1, 2021) | 615.5b |
Gross profit (H1, 2021) | 495.9b |
Gross profit margin (H1, 2021), % | 80.6% |
Net income (H1, 2021) | 72.8b |
EBIT (H1, 2021) | 86.9b |
Market capitalization (30-Apr-2021) | 3.0t |
Closing stock price (30-Apr-2021) | 1.6k |
Cash (30-Sept-2020) | 286.7b |
EV | 3.2t |
| JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 |
|---|---|---|---|---|---|---|---|---|
Depreciation and Amortization | 16.1b | 31.8b | 47.8b | 17.0b | 31.1b | 48.3b | 18.0b | 35.9b |
Inventories | 2.4b | 3.6b | 2.0b | (3.5b) | (4.6b) | (988.0m) | (3.2b) | (2.9b) |
Accounts Payable | (5.9b) | (11.4b) | 44.6b | (45.0b) | (24.5b) | (42.7b) | (30.2b) | (50.8b) |
Cash From Operating Activities | 37.2b | 112.1b | 203.7b | 7.4b | 101.7b | 170.3b | 21.6b | 115.0b |
| JPY | FY, 2018 |
|---|---|
Revenue/Employee | 78.3m |
Financial Leverage | 1.5 x |
Astellas Pharma Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Iota Biosciences | October 15, 2020 | $127.5 m |
| Nanna Therapeutics | April 21, 2020 | £12 m |
| Xyphos | December 26, 2019 | |
| Audentes Therapeutics | December 02, 2019 | $3 b |
| Potenza Therapeutics | December 14, 2018 | $405 m |
| Quethera | August 14, 2018 | £85 m |
| Universal Cells Inc. | February 13, 2018 | |
| Mitobridge | December 01, 2017 | |
| Ogeda | April 02, 2017 | €500 m |
| Ganymed Pharmaceuticals | October 28, 2016 | $1.4 b |
Astellas Pharma Revenue Breakdown
Astellas Pharma revenue breakdown by business segment: 30.7% from XTANDI, 14.8% from Prograf, 12.4% from Betanis/Myrbetriq/BETMIGA and 42.0% from Other
Astellas Pharma revenue breakdown by geographic segment: 34.4% from United States , 28.8% from Japan and 36.7% from Other
Astellas Pharma Cybersecurity Score
Astellas Pharma Environment, Social & Governance (ESG) Ratings
Astellas Pharma Online and Social Media Presence
50.39k Twitter followers
Astellas Pharma has 50.39k Twitter Followers. The number of followers has increased 0.6% month over month and increased 2.6% quarter over quarter
Astellas Pharma's Trends
Twitter Engagement Stats for @AstellasUS
4.4k
Tweets
1.3k
Following
50.4k
Followers
25
Tweets last 30 days
5.8
Avg. likes per Tweet
96%
Tweets with engagement
Astellas Pharma Company Culture
Overall Culture
F
34/100
CEO Rating
F
30/100
Compensation
F
10/100
Astellas Pharma News and Updates
Astellas and MBC BioLabs Announce Winners of Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery and Innovation
KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus
Astellas and Viatris Announce Termination of Co-promotion, Succession of Manufacturing and Marketing Approval, and Transfer of Distribution for Celecox® Tablets
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
Astellas Transfers DIFICLIRTM in Europe, Middle East, Africa and selected CIS to Tillotts Pharma
Astellas Launches a “Contact for Potential Acquisition of Astellas’ R&D Programs” Section on its Corporate Website
Astellas Pharma Blogs
Astellas and WiserCare Announce Collaboration to Improve Patient Experience
Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration
Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting
Astellas Pharma Frequently Asked Questions
When was Astellas Pharma founded?
Astellas Pharma was founded in 1923.
Who are Astellas Pharma key executives?
Astellas Pharma's key executives are Yoshihiko Hatanaka, Shontelle Dodson and Kenji Yasukawa.
How many employees does Astellas Pharma have?
Astellas Pharma has 15,883 employees.
What is Astellas Pharma revenue?
Latest Astellas Pharma annual revenue is ¥1.3 t.
What is Astellas Pharma revenue per employee?
Latest Astellas Pharma revenue per employee is ¥81.9 m.
Who are Astellas Pharma competitors?
Competitors of Astellas Pharma include Nipro Corporation, Hetero and Viatris.
Where is Astellas Pharma headquarters?
Astellas Pharma headquarters is located at 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo.
Where are Astellas Pharma offices?
Astellas Pharma has offices in Tokyo, Shizuoka, Takahagi, Takaoka and in 57 other locations.
How many offices does Astellas Pharma have?
Astellas Pharma has 63 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies